ProKidney Gains Regulatory Momentum as FDA Supports Accelerated Approval Pathway for Rilparencel ProKidney (PROK) has taken a step forward in its regulatory journey with the U.S. Food and Drug Administration formally aligning with the company’s proposed a

#PROK #ProKidney is gaining momentum! The FDA has backed an accelerated approval pathway for rilparencel, its lead therapy for chronic kidney disease—marking a major step toward regulatory success.
prismmarketview.com/prokidney-ga...

#ProKidney #PROK currently leads the PRISM Emerging Biotech Index. Shares are trading up ~50% today and 730% this week following positive Phase 2 trial results. The company will be presenting at H.C. Wainwright Kidney Conference July 14th.

Learn more here: bit.ly/44T9Hb5

ProKidney stock surges after Citi raises price target to $9 Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock surged 65% in pre-market trading on Wednesday, building on Tuesday’s massive 515% gain following positive clinical trial data. The latest jump came after Citi analysts raised their price target on the stock to $9 from $6, citing better-than-expected topline results from the Phase 2 REGEN-007 study evaluating rilparencel in patients with Type 1 and Type 2 diabetes and chronic kidney disease. ProKidney shares closed at $3.73 on Tuesday. Citi analysts increased their probability of success for the treatment to 60%, up 10 percentage points, after the study demonstrated statistically significant efficacy on stabilization of estimated glomerular filtration rate (eGFR) slope in Group 1 patients who received injections in both kidneys. The analysts noted that this endpoint may support accelerated approval in Phase 3 pending FDA confirmation. While the FDA has already indicated that eGFR slope is an acceptable surrogate endpoint, some details regarding required follow-up time and sample sizes still need clarification. The bank’s analysts are awaiting full results with eGFR plots at the American Society of Nephrology conference to better understand the significance of these findings, which reportedly exceeded both management’s and analysts’ expectations. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in PROK, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is PROK one of them?

Click Subscribe #ProKidney #StockMarket #Investing #DiabetesResearch #ClinicalTrials

ProKidney Surges After Positive Phase 2 Results for Chronic Kidney Disease Therapy Shares of ProKidney (PROK) soared more than 580% today following the release of encouraging topline results from its Phase 2 REGEN-007 clinical trial evaluating

ProKidney Shares Surge on Positive CKD Trial Results
#ProKidney ( #PROK) is making waves after reporting encouraging Phase 2 results for its chronic kidney disease therapy, driving investor optimism and momentum in renal innovation.
prismmarketview.com/prokidney-su...

ProKidney stock soars after positive Phase 2 trial results Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock surged 115% after the company reported statistically significant and clinically meaningful positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease (CKD) and diabetes. The late clinical-stage cellular therapeutics company announced that patients in Group 1 of the trial showed a 78% improvement in annual kidney function decline following treatment. The annual decline in estimated glomerular filtration rate (eGFR) slope improved from -5.8 mL/min/1.73m² in the pre-injection period to -1.3 mL/min/1.73m² after the last rilparencel injection, representing a statistically significant difference of 4.6 mL/min/1.73m² per year. Group 2, which tested an exploratory dosing regimen, showed a 50% improvement in kidney function decline, suggesting evidence of a dose response, though this difference was not statistically significant. The REGEN-007 trial evaluated 49 patients who received at least one rilparencel injection across two treatment groups. Group 1 replicated the dosing schedule of the company’s ongoing Phase 3 PROACT 1 study, with patients receiving two scheduled injections approximately three months apart. "We are very encouraged by the REGEN-007 topline results that demonstrated a robust improvement in eGFR slope following treatment with rilparencel in Group 1 as well as evidence of a dose response in Group 2," said Bruce Culleton, M.D., CEO of ProKidney. No rilparencel-related serious adverse events were observed in the study, with the safety profile consistent with previously reported results and comparable to a kidney biopsy. The company plans to submit the full results from REGEN-007 to the American Society of Nephrology’s 2025 Kidney Week as a late-breaking clinical trial. ProKidney is also preparing for an upcoming FDA Type B meeting to confirm its approach to eGFR slope as a surrogate endpoint for accelerated approval. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if PROK is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #ProKidney #StockMarket #Investing #Phase2Trial #HealthcareStocks